U.S. Department of Health and Human Services • National Institutes of Health

Advanced Search

NIAID > Labs & Scientific Resources > Technology Development

Skip Website Tools

Website Tools

Skip Stay Connected

Stay Connected

Social media privacy policy and disclaimers.

Contact Info

NIAID Office of Technology Development
6610 Rockledge Drive, Suite 2800, MSC 6606
Bethesda, MD 20892-6606
(ZIP code for courier: 20817)
Phone:: 301-496-2644
Fax: 301-402-7123

Check out a map of NIH Active Licenses around the world. To see only NIAID licenses, select NIAID from the Institute/Center drop-down list and click Submit. You can also filter the map by fiscal year and country.

External Resources

View a list of outside resources for more information about Technology Development.

Javascript Error

Your browser JavaScript is turned off causing certain features of the NIAID Institute of Allergy and Infectious Diseases web site to work incorrectly. Please visit your browser settings and turn JavaScript on. Read more information on enabling JavaScript.

Technology Development

Skip Content Marketing

Share this:

Translating Scientific Discoveries Into Medical Practice

NIAID has been at the forefront of cutting-edge biomedical research for decades. The work performed in its labs has furthered the understanding of the immune system and led to significant advances in the fields of immunology and infectious disease research. But it's a long path from basic scientific discoveries to approved vaccines, treatments, or diagnostic tools. NIAID is constantly pursuing collaborations with industry and academia to develop its technologies and materials into products that improve public health. The Office of Technology Development facilitates collaborative relationships between NIAID investigators and the broader scientific community.

Technology Development

View Slides

Highlighted Licensing and Collaboration Opportunities

Transmission-Blocking Malaria Vaccine

PSM Peptides as Vaccine Targets Against Methicillin-Resistant Staphylococcus aureus

Infectious Hepatitis E Virus Genotype 3 Recombinants—Prospective Vaccine Candidates and Vector System

Multivalent Vaccines for Rabies Virus and Filoviruses

See the complete list of Recent Licensing and Collaboration Opportunities.

Recent Happenings

United States patent US 8,268,323 was issued on Sept. 18, 2012, for conformationally stabilized HIV envelope immunogens. NIAID inventors: Peter Kwong, Ph.D.; John Mascola, M.D.; Gary Nabel, M.D., Ph.D.; Barna Dey, Ph.D.; Chin-Chin Huang, Ph.D.; Tongqing Zhou, Ph.D.; Ling Xu

NIAID and Altor BioScience Corp. signed a cooperative research and development agreement (CRADA) to study development of soluble, single chain T-cell receptors (scTCRs) specific to HIV epitopes as presented by major histocompatibility complexes (MHCs) using Altor Bioscience’s proprietary scTCR technology. NIAID principal investigator: Mark Connors, M.D.

See the complete list of Technology Development Recent Happenings.